Synteract has closed a deal to acquire Germany's Harrison Clinical Research, rebranding itself as SynteractHCR and expanding its reach to 16 countries.
Neither CRO has disclosed financial details, but the merger brings a total of about 800 employees for SynteractHCR, spread across the U.S., Europe, Israel and South America. Synteract CEO Wendel Barr will lead the new company, with former HCR CEO Benedikt van Nieuwenhove serving as president of European operations.
Separately, the two organizations provided Phase I-IV services, but by joining forces, the pair can offer clinical trial support to biopharma clients around the world, Barr said. "Our longstanding drug development expertise allows us to form a new global leader with enhanced scale and therapeutic breadth, but with the personal approach that we have always taken to working with clients," he said in a statement.
Barr said SynteractHCR wants to become a one-stop shop for emerging and mid-size biotechs, offering services from discovery to post-marketing and spreading its resources to industry hubs around the world.
- read SynteractHCR's announcement